DDInter576 DDInter642
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022.
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enfortumab vedotin
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Disulfiram {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enfortumab vedotin
Disulfiram {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Disulfiram {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Disulfiram {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is downregulated by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Disulfiram {u} (Compound) upregulates {v} (Gene) POLD4
POLD4 {u} (Gene) is upregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Enfortumab vedotin
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Enfortumab vedotin
Disulfiram {u} (Compound) downregulates {v} (Gene) ERBB3
ERBB3 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Disulfiram {u} (Compound) downregulates {v} (Gene) ERBB3
ERBB3 {u} (Gene) is downregulated by {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Disulfiram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Disulfiram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Disulfiram (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enzalutamide (Compound) and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Disulfiram (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Disulfiram (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Disulfiram (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Rosuvastatin (Compound) and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Disulfiram (Compound) upregulates POLD4 (Gene) and POLD4 (Gene) is upregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Enfortumab vedotin
Disulfiram (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Enfortumab vedotin
Disulfiram (Compound) downregulates ERBB3 (Gene) and ERBB3 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Disulfiram (Compound) downregulates ERBB3 (Gene) and ERBB3 (Gene) is downregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin